Skip to main content

MoneyWorks4Me

Aurobindo Pharma informs about updates

11 Nov 2026 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area - Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3).

The above information is a part of company’s filings submitted to BSE. 


Peers
Company Name CMP
Sun Pharma. Inds. 1872.30
Dr. Reddys Labs. 1396.00
Cipla 1420.00
Lupin 1968.95
Zydus Lifesciences 1195.00
View more..